BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 31175983)

  • 1. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
    Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
    Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiocyanate Reduces Motor Impairment in the hMPO-A53T PD Mouse Model While Reducing MPO-Oxidation of Alpha Synuclein in Enlarged LYVE1/AQP4 Positive Periventricular Glymphatic Vessels.
    Reynolds WF; Malle E; Maki RA
    Antioxidants (Basel); 2022 Nov; 11(12):. PubMed ID: 36552550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity.
    Hu D; Sun X; Liao X; Zhang X; Zarabi S; Schimmer A; Hong Y; Ford C; Luo Y; Qi X
    Acta Neuropathol; 2019 Jun; 137(6):939-960. PubMed ID: 30877431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
    Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
    Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.
    Ikeda M; Kawarabayashi T; Harigaya Y; Sasaki A; Yamada S; Matsubara E; Murakami T; Tanaka Y; Kurata T; Wuhua X; Ueda K; Kuribara H; Ikarashi Y; Nakazato Y; Okamoto K; Abe K; Shoji M
    Brain Res; 2009 Jan; 1250():232-41. PubMed ID: 18992718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sigma-1 receptor knockout increases α-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra.
    Hong J; Wang L; Zhang T; Zhang B; Chen L
    Neurobiol Aging; 2017 Nov; 59():171-183. PubMed ID: 28870519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies.
    Hass EW; Sorrentino ZA; Xia Y; Lloyd GM; Trojanowski JQ; Prokop S; Giasson BI
    Acta Neuropathol Commun; 2021 Aug; 9(1):146. PubMed ID: 34454615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.
    Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT
    Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
    Zhang LF; Yu XL; Ji M; Liu SY; Wu XL; Wang YJ; Liu RT
    Food Funct; 2018 Dec; 9(12):6414-6426. PubMed ID: 30462117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.
    Liu CW; Giasson BI; Lewis KA; Lee VM; Demartino GN; Thomas PJ
    J Biol Chem; 2005 Jun; 280(24):22670-8. PubMed ID: 15840579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease.
    Kleinknecht A; Popova B; Lázaro DF; Pinho R; Valerius O; Outeiro TF; Braus GH
    PLoS Genet; 2016 Jun; 12(6):e1006098. PubMed ID: 27341336
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Davis AA; Inman CE; Wargel ZM; Dube U; Freeberg BM; Galluppi A; Haines JN; Dhavale DD; Miller R; Choudhury FA; Sullivan PM; Cruchaga C; Perlmutter JS; Ulrich JD; Benitez BA; Kotzbauer PT; Holtzman DM
    Sci Transl Med; 2020 Feb; 12(529):. PubMed ID: 32024799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rab7 reduces α-synuclein toxicity in rats and primary neurons.
    Szegö EM; Van den Haute C; Höfs L; Baekelandt V; Van der Perren A; Falkenburger BH
    Exp Neurol; 2022 Jan; 347():113900. PubMed ID: 34695425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
    Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein Strains and Their Relevance to Parkinson's Disease, Multiple System Atrophy, and Dementia with Lewy Bodies.
    Graves NJ; Gambin Y; Sierecki E
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropathology of α-synuclein in Parkinson's disease.
    Choong CJ; Mochizuki H
    Neuropathology; 2022 Apr; 42(2):93-103. PubMed ID: 35362115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.